Quantifying patient preferences for systemic atopic dermatitis treatments using a discrete-choice experiment

被引:28
|
作者
Boeri, Marco [1 ]
Sutphin, Jessie [2 ]
Hauber, Brett [2 ,3 ]
Cappelleri, Joseph C. [4 ]
Romero, William [5 ]
Di Bonaventura, Marco [6 ]
机构
[1] RTI Hlth Solut, Belfast, Antrim, North Ireland
[2] RTI Hlth Solut, Res Triangle Pk, NC USA
[3] Univ Washington, Sch Pharm, Comparat Hlth Outcomes Policy & Econ CHOICE Inst, Seattle, WA 98195 USA
[4] Pfizer Inc, Groton, CT 06340 USA
[5] Pfizer Inc, Surrey, England
[6] Pfizer Inc, 235 East 42nd St, New York, NY 10017 USA
关键词
Atopic dermatitis; discrete-choice experiment; maximum acceptable risk; patient preference; CONJOINT-ANALYSIS APPLICATIONS; SKIN PAIN; GUIDELINES; ECZEMA; HEALTH; MANAGEMENT; CARE; PREVALENCE; BURDEN; ADULTS;
D O I
10.1080/09546634.2020.1832185
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Objectives To identify meaningful treatment attributes and quantify patient preferences for attributes of systemic atopic dermatitis (AD) treatments. Materials and methods Qualitative interviews were conducted with adults with moderate-to-severe AD (N = 21) to identify AD treatment attributes that patients consider most important and inform attribute selection for an online discrete-choice experiment (DCE) survey administered to patients in the United States with moderate-to-severe AD. Participants identified probability of clear/almost clear skin at 16 weeks, time to itch relief, mode of administration, and safety risks as very important. DCE data were analyzed using a random-parameters logit model to estimate the relative importance of treatment attributes and maximum acceptable risk. Results A total of 320 respondents completed the DCE survey (74% female; mean age, 35 years). Annual risk of malignancy was the most important attribute, followed by mode of administration, probability of clear skin at 16 weeks, and time to onset of itch relief. Respondents preferred daily oral treatment over injectable treatment. Respondents were willing to accept increases in adverse event risks for improvements in efficacy and mode of administration. Conclusion The findings of this study can help inform joint patient-physician decision making in managing moderate-to-severe AD.
引用
收藏
页码:1449 / 1458
页数:10
相关论文
共 50 条
  • [1] Quantifying Physician Preferences for Systemic Atopic Dermatitis Treatments Using a Discrete-Choice Experiment
    Carrascosa Carrillo, Jose Manuel
    Baselga Torres, Eulalia
    Gilaberte Calzada, Yolanda
    Jurgens Martinez, Yanina Nancy
    Roustan Gullon, Gaston
    Yanguas Bayona, Juan Ignacio
    Gomez Castro, Susana
    Giovanna Ferrario, Maria
    Rebollo Laserna, Francisco Jose
    [J]. DERMATOLOGY AND THERAPY, 2022, 12 (05) : 1197 - 1210
  • [2] Quantifying Physician Preferences for Systemic Atopic Dermatitis Treatments Using a Discrete-Choice Experiment
    José Manuel Carrascosa Carrillo
    Eulalia Baselga Torres
    Yolanda Gilaberte Calzada
    Yanina Nancy Jurgens Martínez
    Gastón Roustan Gullón
    Juan Ignacio Yanguas Bayona
    Susana Gómez Castro
    Maria Giovanna Ferrario
    Francisco José Rebollo Laserna
    [J]. Dermatology and Therapy, 2022, 12 : 1197 - 1210
  • [3] Patient preferences for features of systemic atopic dermatitis therapies: a discrete-choice experiment study
    Kwatra, S.
    Lio, P.
    Calimlim, B.
    Ladizinski, B.
    Davis, J.
    Botha, W.
    Mansfield, C.
    Weidinger, S.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E161 - E162
  • [4] Patient preferences for atopic dermatitis treatments: a discrete choice experiment
    Kwatra, Shawn G.
    Lio, Peter
    Weidinger, Stephan
    Calimlim, Brian
    Ladizinski, Barry
    Vigna, Namita
    Botha, Willings
    Mansfield, Carol
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)
  • [5] PATIENT PREFERENCES FOR SYSTEMIC ATOPIC DERMATITIS TREATMENTS IN THE UK, FRANCE AND SPAIN: A DISCRETE CHOICE EXPERIMENT
    Thomas, C.
    Raibouaa, A.
    Wollenberg, A.
    Capron, J. P.
    Krucien, N.
    Karn, H.
    Tervonen, T.
    [J]. VALUE IN HEALTH, 2020, 23 : S621 - S621
  • [6] Patient and caregiver preferences for haemophilia treatments: A discrete-choice experiment
    Garcia, Viridiana Cano
    Mansfield, Carol
    Pierce, Anna
    Leach, Colton
    Smith, Jane Cavanaugh
    Afonso, Marion
    [J]. HAEMOPHILIA, 2024, 30 (02) : 375 - 387
  • [7] Patient Preferences for Preventive Migraine Treatments: A Discrete-Choice Experiment
    Mansfield, Carol
    Gebben, David J.
    Sutphin, Jessie
    Tepper, Stewart J.
    Schwedt, Todd J.
    Sapra, Sandhya
    Shah, Neel
    [J]. HEADACHE, 2019, 59 (05): : 715 - 726
  • [8] Quantifying Patient Preferences for Treatment Outcomes in AML: A Discrete-Choice Experiment
    Richardson, Daniel R.
    Seo, Jaein
    Smith, Douglas
    Estey, Elihu H.
    O'Donoghue, Bernadette
    Bridges, John F. P.
    [J]. BLOOD, 2018, 132
  • [9] Patient Preferences for Unresectable Hepatocellular Carcinoma Treatments: A Discrete-Choice Experiment
    Li, Daneng
    Tan, Ruoding
    Hernandez, Sairy
    Reilly, Norelle
    Bussberg, Cooper
    Mansfield, Carol
    [J]. CANCERS, 2023, 15 (05)
  • [10] Patient preferences for chronic lymphocytic leukemia treatments: a discrete-choice experiment
    Ravelo, Arliene
    Myers, Kelley
    Brumble, Robyn
    Bussberg, Cooper
    Koffman, Brian
    Manzoor, Beenish S.
    Biondo, Juliana M.
    Mansfield, Carol
    [J]. FUTURE ONCOLOGY, 2024,